What are the challenges and solutions in achieving blood pressure targets in hypertensive patients?

Details

Supervisors

Persu, Alexandre

Faculty

Faculté de pharmacie et des sciences biomédicales

Degree label

Master [120] en sciences pharmaceutiques, à finalité spécialisée

Abstract

Background Hypertension is a leading cause of cardiovascular diseases and affects millions globally. A complex interplay of genetic, environmental, and lifestyle factors influences it. Understanding hypertension mechanisms and developing effective treatments is critical for improving patient outcomes. Aim This dissertation aims to evaluate innovative solutions in hypertension management. By exploring the results of recent clinical trials of Zilebesiran, an innovative RNA interference therapeutic, this research seeks to provide insights into its potential as a standard treatment. Material and Methods The methodology involves thoroughly analysing data from multiple clinical trials, including Phase 1 and Phase 2 studies. Patient characteristics, trial design, primary and secondary endpoints, and safety profiles were meticulously reviewed. The primary endpoint focused on the frequency and severity of adverse events, while secondary endpoints included pharmacodynamics and blood-pressure-lowering efficacy measures. Results and Discussion The trials demonstrated significant systolic and diastolic blood pressure reductions with Zilebesiran, achieving a sustained effect over time. Safety profiles indicated mild to moderate adverse events, with no severe outcomes linked to the treatment. The data suggest that Zilebesiran could be a promising addition to hypertension therapy, providing effective blood pressure control with a favourable safety profile. Conclusion Zilebesiran shows considerable promise as an effective and safe treatment for hypertension. Future studies should focus on long-term outcomes and comparisons with existing therapies to further establish their role in clinical practice. The findings support its potential to significantly improve hypertension management and patient quality of life.